Recormon Use In Pregnancy & Lactation

Pregnancy: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see Pharmacology: Toxicology: Nonclinical Safety under Actions).
For epoetin beta, all safety information with regard to exposure to Epoetin beta (Recormon) during pregnancies has been gained from post marketing experience. A review of the available postmarketing data does not show evidence of a causal association between harmful effects with respect to pregnancy, embryonal/fetal development or postnatal development and treatment with Epoetin beta (Recormon). However in the absence of clinical study data, caution should be exercised when prescribing to pregnant women.
Labor and Delivery: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see Pharmacology: Toxicology: Nonclinical Safety under Actions).
For epoetin beta, all safety information with regard to exposure during labor and delivery has been gained from post marketing experience. No evidence of harmful effects with respect to labor and delivery have been observed. However in the absence of clinical study data, caution should be exercised when prescribing to pregnant women in labor.
Lactation: Only limited experience in human lactation has been gained. Endogenous erythropoietin is excreted in breast milk and readily absorbed by the neonatal gastrointestinal tract. A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with epoetin beta should be made taking into account the benefit of breastfeeding to the child and the benefit of epoetin beta therapy to the woman.